Jinghong Chen

Washington, D.C., United States

Data Reporter at Atlantic Information Services

Freelance Writer at The Globe Post

Featured in: Favicon

aishealth.com Favicon

theglobepost.com Favicon

frontiersin.org Favicon

rsc.org

informa.com Favicon

wbez.org

columbiamissourian.com Favicon

nutraingredients.com Favicon

mmitnetwork.com Favicon

ire.org + 8 more

Articles

Study Shows ‘Insurer-PBMs’ Dominate Medicare Part D, Steer Patients to Their Pharmacies

1 month ago | insights.citeline.com | Jinghong Chen

Study Shows ‘Insurer-PBMs’ Dominate Medicare Part D, Steer Patients to Their Pharmacies An analysis of Medicare Part D and other data found that more than one-third of all pharmacy spending went through pharmacies owned by Cigna, CVS Health, Humana or UnitedHealth Group. PBM-owned pharmacies for specialty and non-specialty drugs filled higher percentages of claims than would be expected without steering, according to a recent study. (Shutterstock)
Computational frameworks transform antagonism to synergy in optimizing combination therapies

Jan 18, 2025 | flipboard.com | Jinghong Chen |Anqi Lin |Aimin Jiang |Chang Qi |Zaoqu Liu |Shuofeng Yuan | +1 more

11 hours agoZeigler Defense: New DNA evidence proves he is not the killerWINTER GARDEN, Fla. — Florida death row inmate William "Tommy" Zeigler has filed a new motion to prove his innocence using new DNA testing.
MA-PD Deductibles Up, PDP Options Down Amid Big Policy Changes in 2025

Jan 6, 2025 | insights.citeline.com | Jinghong Chen

MA-PD Deductibles Up, PDP Options Down Amid Big Policy Changes in 2025 Data illustrates the 2025 Medicare Part D plan landscape, including changes in premiums and plan options. PDP options decreased to the lowest number since 2006. (Shutterstock)
Study Makes Case for Rethinking Medicare Drug Price Negotiation Timeline

Dec 5, 2024 | mmitnetwork.com | Jinghong Chen

Small-molecule drugs and biologics may produce similar health benefits, but because small molecules tend to be priced lower than biologics, they often represent better value, according to a recent Health Affairs study. And the study authors argued those findings suggest it could be worth revising how the Medicare Drug Price Negotiation Program is set up.
The ACA Marketplaces in 2025, at a Glance

Nov 7, 2024 | mmitnetwork.com | Jinghong Chen

HealthCare.gov enrollees have more health plan options in 2025 compared to previous years, yet the average benchmark plan premium in states that use the federal enrollment platform increased modestly, according to CMS. In most states, the open enrollment period for Affordable Care Act marketplace coverage runs from Nov. 1, 2024, to Jan. 15, 2025.
Analyses Paint Mixed Picture of Stand-Alone PDP Costs in 2025

Oct 17, 2024 | mmitnetwork.com | Jinghong Chen

Premiums for many stand-alone Medicare Part D Prescription Drug Plans will go up moderately in 2025, while the number of PDP options for beneficiaries will drop significantly, according to AIS Health’s analysis of the recently released CMS Medicare Advantage and Part D landscape files.
A Map View Of US Biosimilar Uptake

Oct 16, 2024 | insights.citeline.com | Jinghong Chen

A Map View Of US Biosimilar Uptake30 Sep 2024 • By Jinghong ChenTexas comes out on top for biosimilar uptake, but how do the other US states compare? Geographical data can pinpoint which states are embracing biosimilars, and which have a way to go.
Satisfaction With PBM Industry Dips to Record Low in 2024

Oct 3, 2024 | mmitnetwork.com | Jinghong Chen

Overall satisfaction with PBMs is at a decade-long low this year, according to the 2024 Pharmacy Benefit Manager Customer Satisfaction Report, published by Pharmaceutical Strategies Group, an EPIC company. The report also showed that payers were seeking improvements in the PBM industry and were willing to be part of the disruptive change.
A Map View Of US Biosimilar Uptake

Sep 29, 2024 | invivo.citeline.com | Jinghong Chen

Data Executive Summary Texas comes out on top for biosimilar uptake, but how do the other US states compare? Geographical data can pinpoint which states are embracing biosimilars, and which have a way to go. Source: Shutterstock Existing Subscriber? Sign in to continue reading. New to In Vivo? Start a free trial today!
Satisfaction With PBM Industry Dips to Record Low in 2024

Sep 26, 2024 | mmitnetwork.com | Jinghong Chen

Overall satisfaction with PBMs is at a decade-long low this year, according to the 2024 Pharmacy Benefit Manager Customer Satisfaction Report, published by Pharmaceutical Strategies Group, an EPIC company. The report also showed that payers were seeking improvements in the PBM industry and were willing to be part of the disruptive change.